Note: A short video is included that explains why the cure rates mirror the clinical trial cure rates – highly recommended – Alan
Real-world results for hepatitis C drugs have been very closely aligned to the clinical trial outcomes, which is likely due to a combination of factors, such as the effectiveness of the agents and better knowledge of using direct-acting antivirals, according to Gail Bridges, PharmD, of Accredo Health.
How do the real-world results of the hepatitis C virus drugs Harvoni and Viekira Pak hold up to the results that were reported in the clinical trials?
Our data indicate that Accredo’s patients achieve results that are right on point with the clinical trials. In our study patients achieved an average sustained viral response rate, which is really the clinical surrogate marker for cure, of 96%. And this was on par with the mid-90% range that each of these individual therapies described in their clinical trials.